Company profile
Pazoo, Inc.
OTC: PZOO · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ East Hanover, NJReports USD
#1164 of 1,420 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 30
v0.1 · 5/100 weight · pillars only
↑ Piotroski F, listing tenure · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$4.8M
Employees
3
as of 2026-08-29
Market cap
$26.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02017
Net income-$4.8M-$4.8M2017
Operating income-$2.2M-$2.2M2017
Total assets$129.5k$129.5k2017
Liabilities$11.2M$11.2M2017
Equity-$11.1M-$11.1M2017
Revenue trend
FY2011 – FY2017 · USD
FY11
FY12
FY13
FY14
FY15
FY16
FY17
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Pazoo, Inc.’s revenue?
Pazoo, Inc. booked $0 in FY2017 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Health Advance Inc.——Transnational Cannabis Ltd.——Spencer Pharmaceutical Inc.——Scopus BioPharma Inc.——Healthcare Solutions Management Group, Inc.——Stem Cell Authority, Ltd.——Key facts
CEOSteven Basloe
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersEast Hanover, NJ
ExchangeOTC: PZOO
Employees3
IPO date2012-06-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.